Johnson & Johnson Reports 12-Month Data from OMNY-AF Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Should l Buy JNJ?
Johnson & Johnson announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation, during the 31st Annual AF Symposium in Boston. Initial results for 12-month outcomes across the 30-patient pilot cohort show investigators achieved 100% acute procedural success with no procedure-associated adverse events, while 56.7% of cases were performed with zero fluoroscopy and 90% of patients achieved primary effectiveness at 12 months. "The 12-month data provide encouraging early evidence on the OMNY-AF study with promising safety outcomes - no procedure-related adverse events or MRI-detected cerebral lesions - across eight centers in the pilot phase. In my cases during the ongoing OMNY-AF trial, the seamless integration of advanced mapping, ultrasound, and PF Index with contact force were valuable for precise and efficient pulsed field energy delivery," said Dinesh Sharma, M.D., Section Head of Cardiac Electrophysiology at the Naples Heart Institute, the study presenting author.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 218.50 USD with a low forecast of 190.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 237.790
Low
190.00
Averages
218.50
High
240.00
Current: 237.790
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Confusion in AI Competition
- Investor Sentiment Shift: Following earnings calls from tech giants like Microsoft, Google, and Amazon, investor confusion about future directions led to Amazon losing over $300 billion in market cap, reflecting strong skepticism regarding its $200 billion AI investment plan.
- Capital Expenditure Comparison: Google announced an increase in capital expenditures to $175 billion to $185 billion, exceeding the expected $115 billion to $120 billion, indicating a proactive approach in AI despite challenges from slowing ad revenues.
- Changing Competitive Landscape: With Alphabet's ongoing investments and successes in AI, YouTube's user base has grown to 750 million, and Waymo's self-driving business is outpacing Tesla, suggesting a strengthening competitive advantage that may attract more investor interest.
- Mixed Market Reactions: Despite OpenAI and Anthropic's strong performance in AI, Microsoft's Copilot sales have been disappointing, highlighting investor concerns about its future growth and reflecting differing levels of confidence across companies.
See More
Analysis of Strong Dividend Stocks: Johnson & Johnson and Medtronic
- Dividend Growth Performance: Johnson & Johnson (JNJ) extended its dividend growth streak to 63 years in 2025 with a 4.8% increase, boasting a 2.2% dividend yield that is nearly double the S&P 500, showcasing its exceptional performance in dividend growth and enhancing investor confidence.
- Financial Health: Last year, Johnson & Johnson generated $20 billion in free cash flow, easily covering its $12.4 billion in dividend payouts, and holds a AAA credit rating, ensuring its ability to maintain dividend payments and stability for future investments.
- R&D Investment: Johnson & Johnson invested $14.7 billion in R&D and completed a $14.6 billion acquisition of Intra-Cellular Therapies, solidifying its leadership in neuroscience, which will further drive its earnings and dividend growth.
- Medtronic's Dividend Stability: Medtronic (MDT) achieved its 48th consecutive dividend increase in fiscal year 2025 with a 2.8% yield, supported by $5.2 billion in free cash flow that comfortably covers $3.6 billion in dividends, reflecting its strong financial position and growth potential.
See More
Investors Nervous About Robinhood's Bitcoin Correlation
- Labor Data Impact: The upcoming nonfarm payroll report on Wednesday is expected to show an addition of 80,000 jobs, and if the data comes in weak, it could lead the Fed to continue cutting rates, which would positively impact the stock market, reflecting concerns about economic slowdown.
- CVS Health Earnings Outlook: CVS Health is set to report quarterly results on Tuesday, and despite being affected by the Trump administration's proposed reimbursement rates for Medicare Advantage, Cramer believes CEO David Joyner's management is impressive and the stock is worth owning.
- DuPont Performance Highlights: DuPont's earnings report on the same day is expected to showcase CEO Lori Koch's success in improving the company's performance, with the stock soaring 58% over the past six months, reflecting the effectiveness of its electronics business spin-off strategy.
- Robinhood Trading Risks: Robinhood will report earnings on Tuesday, and due to its close correlation with cryptocurrency markets, investors are concerned, as the stock has dropped nearly 27% year-to-date, significantly underperforming the S&P 500's 1.3% gain.
See More
Johnson & Johnson Releases OMNY-AF Study Data
- Study Success Rate: The OMNY-AF study reported a 100% acute procedural success rate among 30 patients with no procedure-related adverse events, indicating the platform's potential in treating paroxysmal atrial fibrillation and possibly enhancing future clinical applications.
- Fluoroscopy-Free Procedures: Notably, 56.7% of cases were performed without fluoroscopy, and 90% of patients achieved primary effectiveness at 12 months, which not only reduces patient radiation exposure risks but may also enhance patient treatment experience and satisfaction.
- Multi-Center Trial: Conducted across over 40 sites in the U.S. and Australia, the OMNY-AF study highlights Johnson & Johnson's extensive footprint in cardiac electrophysiology, with large-scale data supporting the efficacy and safety of its technologies in the future.
- VARIPULSE Platform Data: The VARIPULSE platform demonstrated a low neurovascular event rate of 0.22% in 6,811 patients, further validating its safety profile and potentially increasing physician confidence in the technology, thereby promoting its clinical adoption.
See More
OMNY-AF Study Reports 90% Freedom from AFib at 12 Months
- Significant Study Results: The OMNY-AF trial demonstrated that 90% of the 30 patients achieved freedom from atrial fibrillation (AFib) at 12 months, with a 100% acute procedural success rate, underscoring the effectiveness and safety of the OMNYPULSE platform.
- No Adverse Events: Conducted across over 40 centers, the study reported no procedure-related adverse events throughout the trial, further reinforcing confidence in the OMNYPULSE platform's application in cardiac electrophysiology.
- Outstanding VARIPULSE Performance: Following workflow enhancements, the VARIPULSE platform exhibited a low neurovascular event rate of just 0.22% in 6,811 patients, demonstrating its safety and efficacy in clinical applications and supporting broader adoption of this technology.
- Commitment to Continuous Innovation: Johnson & Johnson is dedicated to evidence-driven innovation that enhances patient care, leveraging the leading CARTO 3 system technology to advance the field of cardiac electrophysiology and ensure safer, more effective treatment options for patients.
See More
Soft Jobs Report Could Impact Stock Market Next Week
- Job Data Focus: Cramer emphasized the importance of the nonfarm payroll report due next Wednesday, suggesting that a soft reading could lead the Fed to continue cutting rates, which would positively impact the stock market and reflect market expectations of economic slowdown.
- Earnings Reports Ahead: Several companies, including CVS Health, Robinhood, and DuPont, are set to report earnings next week; Cramer believes CVS is the only drug retailer worth owning amid Medicare reform, showcasing its competitive edge in the market.
- DuPont's Strong Performance: Cramer anticipates that DuPont's earnings report will highlight CEO Lori Koch's effective management, particularly after the spinoff of its electronics business, with the stock soaring 58% over the past six months, indicating the success of the company's restructuring.
- McDonald's and Cisco Outlook: Cramer noted that McDonald's maintains a competitive advantage despite beef inflation, while Cisco's stock has risen 10% year-to-date, with both earnings reports expected to provide critical market signals for investors.
See More
Investor Confusion in AI Competition
- Investor Sentiment Shift: Following earnings calls from tech giants like Microsoft, Google, and Amazon, investor confusion about future directions led to Amazon losing over $300 billion in market cap, reflecting strong skepticism regarding its $200 billion AI investment plan.
- Capital Expenditure Comparison: Google announced an increase in capital expenditures to $175 billion to $185 billion, exceeding the expected $115 billion to $120 billion, indicating a proactive approach in AI despite challenges from slowing ad revenues.
- Changing Competitive Landscape: With Alphabet's ongoing investments and successes in AI, YouTube's user base has grown to 750 million, and Waymo's self-driving business is outpacing Tesla, suggesting a strengthening competitive advantage that may attract more investor interest.
- Mixed Market Reactions: Despite OpenAI and Anthropic's strong performance in AI, Microsoft's Copilot sales have been disappointing, highlighting investor concerns about its future growth and reflecting differing levels of confidence across companies.
See More
Analysis of Strong Dividend Stocks: Johnson & Johnson and Medtronic
- Dividend Growth Performance: Johnson & Johnson (JNJ) extended its dividend growth streak to 63 years in 2025 with a 4.8% increase, boasting a 2.2% dividend yield that is nearly double the S&P 500, showcasing its exceptional performance in dividend growth and enhancing investor confidence.
- Financial Health: Last year, Johnson & Johnson generated $20 billion in free cash flow, easily covering its $12.4 billion in dividend payouts, and holds a AAA credit rating, ensuring its ability to maintain dividend payments and stability for future investments.
- R&D Investment: Johnson & Johnson invested $14.7 billion in R&D and completed a $14.6 billion acquisition of Intra-Cellular Therapies, solidifying its leadership in neuroscience, which will further drive its earnings and dividend growth.
- Medtronic's Dividend Stability: Medtronic (MDT) achieved its 48th consecutive dividend increase in fiscal year 2025 with a 2.8% yield, supported by $5.2 billion in free cash flow that comfortably covers $3.6 billion in dividends, reflecting its strong financial position and growth potential.
See More
Investors Nervous About Robinhood's Bitcoin Correlation
- Labor Data Impact: The upcoming nonfarm payroll report on Wednesday is expected to show an addition of 80,000 jobs, and if the data comes in weak, it could lead the Fed to continue cutting rates, which would positively impact the stock market, reflecting concerns about economic slowdown.
- CVS Health Earnings Outlook: CVS Health is set to report quarterly results on Tuesday, and despite being affected by the Trump administration's proposed reimbursement rates for Medicare Advantage, Cramer believes CEO David Joyner's management is impressive and the stock is worth owning.
- DuPont Performance Highlights: DuPont's earnings report on the same day is expected to showcase CEO Lori Koch's success in improving the company's performance, with the stock soaring 58% over the past six months, reflecting the effectiveness of its electronics business spin-off strategy.
- Robinhood Trading Risks: Robinhood will report earnings on Tuesday, and due to its close correlation with cryptocurrency markets, investors are concerned, as the stock has dropped nearly 27% year-to-date, significantly underperforming the S&P 500's 1.3% gain.
See More
Johnson & Johnson Releases OMNY-AF Study Data
- Study Success Rate: The OMNY-AF study reported a 100% acute procedural success rate among 30 patients with no procedure-related adverse events, indicating the platform's potential in treating paroxysmal atrial fibrillation and possibly enhancing future clinical applications.
- Fluoroscopy-Free Procedures: Notably, 56.7% of cases were performed without fluoroscopy, and 90% of patients achieved primary effectiveness at 12 months, which not only reduces patient radiation exposure risks but may also enhance patient treatment experience and satisfaction.
- Multi-Center Trial: Conducted across over 40 sites in the U.S. and Australia, the OMNY-AF study highlights Johnson & Johnson's extensive footprint in cardiac electrophysiology, with large-scale data supporting the efficacy and safety of its technologies in the future.
- VARIPULSE Platform Data: The VARIPULSE platform demonstrated a low neurovascular event rate of 0.22% in 6,811 patients, further validating its safety profile and potentially increasing physician confidence in the technology, thereby promoting its clinical adoption.
See More
OMNY-AF Study Reports 90% Freedom from AFib at 12 Months
- Significant Study Results: The OMNY-AF trial demonstrated that 90% of the 30 patients achieved freedom from atrial fibrillation (AFib) at 12 months, with a 100% acute procedural success rate, underscoring the effectiveness and safety of the OMNYPULSE platform.
- No Adverse Events: Conducted across over 40 centers, the study reported no procedure-related adverse events throughout the trial, further reinforcing confidence in the OMNYPULSE platform's application in cardiac electrophysiology.
- Outstanding VARIPULSE Performance: Following workflow enhancements, the VARIPULSE platform exhibited a low neurovascular event rate of just 0.22% in 6,811 patients, demonstrating its safety and efficacy in clinical applications and supporting broader adoption of this technology.
- Commitment to Continuous Innovation: Johnson & Johnson is dedicated to evidence-driven innovation that enhances patient care, leveraging the leading CARTO 3 system technology to advance the field of cardiac electrophysiology and ensure safer, more effective treatment options for patients.
See More
Soft Jobs Report Could Impact Stock Market Next Week
- Job Data Focus: Cramer emphasized the importance of the nonfarm payroll report due next Wednesday, suggesting that a soft reading could lead the Fed to continue cutting rates, which would positively impact the stock market and reflect market expectations of economic slowdown.
- Earnings Reports Ahead: Several companies, including CVS Health, Robinhood, and DuPont, are set to report earnings next week; Cramer believes CVS is the only drug retailer worth owning amid Medicare reform, showcasing its competitive edge in the market.
- DuPont's Strong Performance: Cramer anticipates that DuPont's earnings report will highlight CEO Lori Koch's effective management, particularly after the spinoff of its electronics business, with the stock soaring 58% over the past six months, indicating the success of the company's restructuring.
- McDonald's and Cisco Outlook: Cramer noted that McDonald's maintains a competitive advantage despite beef inflation, while Cisco's stock has risen 10% year-to-date, with both earnings reports expected to provide critical market signals for investors.
See More
